Predictive value of laboratory markers in the development of cardiac events in patients with stable coronary artery disease after elective endovascular revascularization

Aim      To reveal a relationship between preprocedural laboratory data and adverse cardiac outcomes (CO) in patients with stable ischemic heart disease (IHD) following elective endovascular revascularization (ER).

Material and methods  This study included 225 patients with IHD admitted for treatment to the Research Institute of Cardiology of the Tomsk National Research Medical Center. The study included patients with documented IHD and hemodynamically significant coronary stenoses requiring elective ER. Patients were divided into groups based on the presence of complications: group 1, 98 patients with adverse CO and group 2, 127 patients without adverse CO. Besides evaluation of complaints, history, and objective status, general clinical and biochemical tests were performed for all patients. Concentration of glycated hemoglobin (НbА1с) was measured by immunoturbidimetry (DiaSys Diagnostic Systems). Serum concentrations of insulin, interleukin-6 (IL-6), endothelin 1 (ET-1), and homocysteine were measured by enzyme immunoassay. Blood lipid profile was determined by enzymatic colorimetry (DiaSys). Content of non-high-density lipoprotein (non-HDL) cholesterol (CS) was calculated as: CS – HDL CS. Insulin resistance (IR) was assessed by the HOMА-IR index. IR was diagnosed at the index of 2.77. Statistical analyses were performed with Statistica 10.0 and Medcalc 19.2.6 software.

Results A one-way regression analysis identified predictors for adverse CO following ER. The most significant predictors were fibrinogen (odds ratio (OR), 1.430; 95 % confidence interval (CI), 1.027–1.990), HbA1c (OR 1.825; 95 % CI, 1.283–2.598), homocysteine (OR, 1.555; 95 % CI, 1.348–1.794), ET-1 (OR, 94.408; 95 % CI, 16.762–531.720), triglycerides (TG)/glucose ratio (OR 1.815; 95 % CI, 1.155–2.853). Based on selected factors, logistic regression models were constructed. However, not all models had a high prognostic power. Only concentrations of ET-1 and homocysteine showed a high prognostic capability in respect of the adverse outcome (88.3 and 85.7 %, respectively).

Conclusion      For patients with IHD, the prognostic capability of ET-1 and homocysteine with respect of the risk for adverse CO following ER was the highest compared to other markers. The results of the study are completely consistent with data of literature and can be successfully used in clinical practice for optimizing the medical care of patients after elective ER.

1. Mansurova J.A., Karazhanova L.K. Independent Predictors of Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome Aſter Percutaneous Coronary Intervention During Hospitalization. Kardiologiia. 2018;58(12):22–9. DOI: 10.18087/cardio.2018.12.10205

2. Svarovskaya A.V., Teplyakov A.T., Gusakova A.M., GarganeevaA.A. Role of markers of inflammation and endothelial dysfunction intheprognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome aſter coronary stenting. Kardiologiia. 2020;60(8):98–105. DOI: 10.18087/cardio.2020.8.n966

3. Windecker S, Stortecky S, Stefanini GG, daCosta BR, Rutjes AW, Di Nisio M et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859. DOI: 10.1136/bmj.g3859

4. Fatenkov O.V., Simerzin V.V., Gagloeva I.V., Galkina M.A., Panisheva Ya.A., Krasovskaya M.A. et al. Endothelial dysfunction as predictor of subclinical and manifest atherosclerosis. Science and Innovations inMedicine. 2018;3(11):39–46.

5. Guddeti RR, Prasad A, Matsuzawa Y, Aoki T, Rihal C, Holmes D et al. Role of endothelin in microvascular dysfunction following percutaneous coronary intervention for non-ST elevation acute coronary syndromes: a single-centre randomised controlled trial. Open Heart. 2016;3(2):e000428. DOI: 10.1136/openhrt-2016-000428

6. Perez AL, Grodin JL, Wu Y, Hernandez AF, Butler J, Metra M et al. Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy: Endothelin-1 in acute HF. European Journal of Heart Failure. 2016;18(3):290–7. DOI: 10.1002/ejhf.456

7. Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. European Journal of Heart Failure. 2017;19(2):167–76. DOI: 10.1002/ejhf.656

8. Li X-Y, Zhao S, Fan X-H, Chen K-P, Hua W, Liu Z-M et al. Plasma big endothelin-1 is an effective predictor for ventricular arrythmias and end-stage events in primary prevention implantable cardioverter- defibrillator indication patients. Journal of Geriatric Cardiology. 2020;17(7):427–33. DOI: 10.11909/j.issn.1671-5411.2020.07.003

9. Hartopo AB, Sukmasari I, Puspitawati I, Setianto BY. Serum Endothelin-1 Correlates with Myocardial Injury and Independently Predicts Adverse Cardiac Events in Non-ST-Elevation Acute Myocardial Infarction. International Journal of Vascular Medicine. 2020;2020:9260812. DOI: 10.1155/2020/9260812

10. Rehman T, Shabbir MA, Inam‐Ur‐Raheem M, Manzoor MF, Ahmad N, Liu Z et al. Cysteine and homocysteine as biomarker of various diseases. Food Science & Nutrition. 2020;8(9):4696–707. DOI: 10.1002/fsn3.1818

11. Ostrakhovitch EA, Tabibzadeh S. Homocysteine and age-associated disorders. Ageing Research Reviews. 2019;49:144–64. DOI: 10.1016/j.arr.2018.10.010

12. Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutrition Journal. 2015;14(1):6. DOI: 10.1186/1475-2891-14-6

13. Shiao SPK, Lie A, Yu CH. Meta-analysis of homocysteine-related factors on the risk of colorectal cancer. Oncotarget. 2018;9(39):25681–97. DOI: 10.18632/oncotarget.25355

14. Li S, Sun L, Qi L, Jia Y, Cui Z, Wang Z et al. Effect of High Homocysteine Level on the Severity of Coronary Heart Disease and Prognosis Aſter Stent Implantation. Journal of Cardiovascular Pharmacology. 2020;76(1):101–5. DOI: 10.1097/FJC.0000000000000829

15. Zhang Z, Xiao S, Yang C, Ye R, Hu X, Chen X. Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes Aſter Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis. Cardiovascular Drugs and Therapy. 2019;33(3):353–61. DOI: 10.1007/s10557-019-06866-0